POM: Prescription only medicine
This information is intended for use by health professionals
Fluorouracil Injection, 50 mg/ml, solution for injection
One vial of Fluorouracil Injection contains:
500 mg fluorouracil in 10 ml solution (50 mg/ml)
1000 mg fluorouracil in 20 ml solution (50 mg/ml)
2500 mg fluorouracil in 50 ml solution (50 mg/ml)
5000 mg fluorouracil in 100 ml solution (50 mg/ml)
Excipient with known effect: Sodium
For a full list of excipients, see section 6.1.
Solution for injection
Fluorouracil Injection, 50 mg/ml, solution for injection is a clear, colourless or almost colourless solution.
Fluorouracil Injection, 50 mg/ml, solution for injection, may be used alone or in combination, for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.
Routes of administration:
Fluorouracil Injection can be given by intravenous injection or intravenous or intra-arterial infusion.
Selection of an appropriate dose and treatment regime depends upon the condition of the patient, the type of carcinoma being treated and whether fluorouracil is to be administered alone or in combination with other therapy. Initial treatment should be given in hospital and the total daily dose should not exceed 1 gram. It is customary to calculate the dose in accordance with the patient's actual bodyweight unless there is obesity, oedema or some other form of abnormal fluid retention such as ascites. In this case, ideal weight is used as the basis for calculation.
Reduction of the dose is advisable in patients with any of the following:
2. Major surgery within preceding 30 days.
3. Reduced bone marrow function.
4. Impaired hepatic or renal function.
The following regimens have been recommended for use as a single agent:
This may be in the form of an infusion or an injection, the former usually being preferred because of lesser toxicity.
15 mg/kg bodyweight but not more than 1 g per infusion, diluted in 500 ml of 5 % glucose or 0.9 % NaCl injection and given by intravenous infusion at a rate of 40 drops per minute over 4 hours. Alternatively the daily dose may be infused over 30 – 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 – 15 g has been reached.
12 mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6 mg/kg on alternate days for 3 further doses. An alternative regime is 15 mg/kg as a single intravenous injection once a week throughout the course.
5 – 7.5 mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.
An initial intensive course may be followed by maintenance therapy providing there are no significant toxic effects. In all instances, toxic side effects must disappear before maintenance therapy is started.
The initial course of fluorouracil can be repeated after an interval of 4 to 6 weeks from the last dose or, alternatively, treatment can be continued with intravenous injections of 5 – 15 mg/kg bodyweight at weekly intervals.
This sequence constitutes a course of therapy. Some patients have received up to 30 g at a maximum rate of 1 g daily. A more recent alternative method is to give 15 mg/kg IV once a week throughout the course of treatment. This obviates the need for an initial period of daily administration.
In combination with Irradiation: Irradiation combined with fluorouracil has been found to be useful in the treatment of certain types of metastatic lesions in the lungs and for the relief of pain caused by recurrent, inoperable growth. The standard dose of fluorouracil should be used.
No recommendations are made regarding the use of Fluorouracil in children.
Fluorouracil should be used in the elderly with similar considerations as with normal adult doses.
Fluorouracil is contraindicated in seriously debilitated patients or those with bone marrow depression after radiotherapy or treatment with other antineoplastic agents.
Fluorouracil is strictly contraindicated in pregnant or breast feeding women.
Fluorouracil should not be used in the management of non-malignant disease.
Fluorouracil is contraindicated in patients who have had a serious hypersensitivity reaction to previous doses of fluorouracil or any of its constituents.
Recent or concomitant treatment with brivudine(see also sections 4.4 and 4.5 for drug interaction).
Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4).
It is recommended that fluorouracil should only be given by, or under the strict supervision of, a qualified physician who is conversant with the use of potent antimetabolites.
All patients should be admitted to hospital for initial treatment.
Adequate treatment with fluorouracil is usually followed by leukopenia, the lowest white blood cell (W.B.C.) count commonly being observed between the 7th and 14th day of the first course, but occasionally being delayed for as long as 20 days.
The count usually returns to normal by the 30th day. Daily monitoring of platelet and W.B.C. count is recommended and treatment should be stopped if platelets fall below 100,000 per mm3 or the W.B.C. count falls below 3,500 per mm3. If the total count is less than 2,000 per mm3, and especially if there is granulocytopenia, it is recommended that the patient be placed in protective isolation in the hospital and treated with appropriate measures to prevent systemic infection.
Treatment should also be stopped at the first sign of oral ulceration or if there is evidence of gastrointestinal side effects such as stomatitis, diarrhoea, bleeding from the G.I. tract or haemorrhage at any site. The ratio between effective and toxic dose is small and therapeutic response is unlikely without some degree of toxicity. Care must be taken therefore, in the selection of patients and adjustment of dosage.
Fluorouracil should be used with caution in patients with reduced renal or liver function or jaundice.
Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, arrhythmias, myocarditis, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation). These adverse events are more common in patients receiving continuous infusion of 5-fluorouracil rather than bolus injection. Prior history of coronary artery disease may be a risk factor for cardiac adverse reactions. Care should therefore be exercised in treating patients who experienced chest pain during courses of treatment, or patients with a history of heart disease. Cardiac function should be regularly monitored during treatment with fluorouracil. In case of severe cardiotoxicity the treatment should be discontinued.
Cases of encephalopathies (including hyperammonaemic encephalopathy, leukoencephalopathy) associated with 5-fluorouracil treatment have been reported from post-marketing sources. Signs or symptoms of encephalopathy are altered mental status, confusion, disorientation, coma or ataxia. If a patient develops any of these symptoms withhold treatment and test serum ammonia levels immediately. In case of elevated serum ammonia levels initiate ammonia-lowering therapy.
Caution is necessary when administering fluorouracil to patients with renal and/or hepatic impairment. Patients with impaired renal and/or hepatic function may have an increased risk for hyperammonaemia and hyperammonaemic encephalopathy.
Dihydropyrimidine dehydrogenase (DPD) deficiency
DPD activity is rate limiting in the catabolism of 5-fluorouracil (see Section 5.2). Patients with DPD deficiency are therefore at increased risk of fluoropyrimidines-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity.
DPD-deficiency related toxicity usually occurs during the first cycle of treatment or after dose increase.
Complete DPD deficiency
Complete DPD deficiency is rare (0.01-0.5% of Caucasians). Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and must not be treated with Fluorouracil Injection 50 mg/ml (see section 4.3).
Partial DPD deficiency
Partial DPD deficiency is estimated to affect 3-9% of the Caucasian population. Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity. DPD deficiency should be considered as a parameter to be taken into account in conjunction with other routine measures for dose reduction. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
Testing for DPD deficiency
Phenotype and/or genotype testing prior to the initiation of treatment with Fluorouracil Injection 50 mg/ml is recommended despite uncertainties regarding optimal pre-treatment testing methodologies. Consideration should be given to applicable clinical guidelines.
Genotypic characterisation of DPD deficiency
Pre-treatment testing for rare mutations of the DPYD gene can identify patients with DPD deficiency.
The four DPYD variants c.1905+1G>A [also known as DPYD*2A], c.1679T>G [DPYD*13], c.2846A>T and c.1236G>A/HapB3 can cause complete absence or reduction of DPD enzymatic activity. Other rare variants may also be associated with an increased risk of severe or life-threatening toxicity.
Certain homozygous and compound heterozygous mutations in the DPYD gene locus (e.g. combinations of the four variants with at least one allele of c.1905+1G>A or c.1679T>G) are known to cause complete or near complete absence of DPD enzymatic activity.
Patients with certain heterozygous DPYD variants (including c.1905+1G>A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants) have increased risk of severe toxicity when treated with fluoropyrimidines.
The frequency of the heterozygous c.1905+1G>A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A>T, 2.6-6.3% for c.1236G>A/HapB3 variants and 0.07 to 0.1% for c.1679T>G.
Data on the frequency of the four DPYD variants in other populations than Caucasian is limited. At the present, the four DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3) are considered virtually absent in populations of African (-American) or Asian origin.
Phenotypic characterisation of DPD deficiency
For phenotypic characterisation of DPD deficiency, the measurement of pre-therapeutic blood levels of the endogenous DPD substrate uracil (U) in plasma is recommended.
Elevated pre-treatment uracil concentrations are associated with an increased risk of toxicity. Despite uncertainties on uracil thresholds defining complete and partial DPD deficiency, a blood uracil level ≥ 16 ng/ml and < 150 ng/ml should be considered indicative of partial DPD deficiency and associated with an increased risk for fluoropyrimidine toxicity. A blood uracil level ≥ 150 ng/ml should be considered indicative of complete DPD deficiency and associated with a risk for life-threatening or fatal fluoropyrimidine toxicity.
5-Fluorouracil Therapeutic drug monitoring (TDM)
TDM of 5-fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions by reducing toxicities and improving efficacy. AUC is supposed to be between 20 and 30mg x h/L.
Brivudine must not be administered concomitantly with Fluorouracil. Fatal cases have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of Fluorouracil therapy. Treatment with brivudine can be started 24 hours after the last dose of Fluorouracil (see section 4.3 and 4.5).
In the event of accidental administration of brivudine to patients being treated with Fluorouracil, effective measures should be taken to reduce the toxicity of Fluorouracil. Immediate admission to hospital is recommended. All measures should be initiated to prevent systemic infections and dehydration.
Patients taking phenytoin concomitantly with fluorouracil should undergo regular testing because of the possibility of an elevated plasma level of phenytoin.
10 ml vial
This medicinal product contains 82.37 mg sodium per 10 ml vial, equivalent to 4.12% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
20 ml vial
This medicinal product contains 164.75 mg sodium per 20 ml vial, equivalent to 8.24% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
50 ml vial
This medicinal product contains 411.87 mg sodium per dose, equivalent to 20.59% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 20.59% of the WHO recommended maximum daily intake for sodium.
Fluorouracil Injection, 50 mg/ml, solution for injection, is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
100 ml vial
This medicinal product contains 823.75 mg sodium per dose, equivalent to 41.19% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 41.19% of the WHO recommended maximum daily intake for sodium.
Fluorouracil Injection, 50 mg/ml, solution for injection, is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
Various agents have been reported to biochemically modulate the antitumour efficacy or toxicity of fluorouracil, common drugs include methotrexate, metronidazole, leucovorin as well as allopurinol and cimetidine which can affect the availability of the active drug.
Marked elevations of prothrombin time and INR have been reported in a few patients stabilised on warfarin therapy following initiation of fluorouracil regimes.
A clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described.
This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with Fluorouracil (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of Fluorouracil therapy. Treatment with brivudine can be started 24 hours after the last dose of Fluorouracil.
Where phenytoin and fluorouracil have been administered concomitantly, there have been reports of elevated plasma levels of phenytoin, resulting in symptoms of phenytoin intoxication (see 4.4).
Fluorouracil should be avoided in combination with clozapine due to the increased risk of agranulocytosis.
Fluorouracil is strictly contraindicated in pregnant and breast feeding women.
Fluorouracil may induce side effects such as nausea and vomiting which could interfere with driving or the use of heavy machinery.
The most commonly reported undesirable effects are diarrhoea, nausea. Leukopenia is also very common and the precautions described above should be followed.
Very common (≥ 1/10)
Common (≥ 1/100, < 1/10)
Uncommon (≥ 1/1,000, < 1/100)
Rare (≥ 1/10,000, < 1/1,000)
Very rare (< 1/10,000), not known
Infections and infestations
Blood and lymphatic system disorders
Leukopenia, myelosuppression, neutropenia, granulocytopenia, thrombocytopenia, anemia, pancytopenia
Immune system disorders
Anaphylactic reaction, anaphylactic shock
Increase of T4 (total thyroxin), increase of T3 (total trijodthyronin)
Metabolism and nutrition disorders
Nervous system disorders
Extrapyramidalmotoric disturbances, cerebellar disturbances, cortical disturbances, nystagmus, headache, vertigo, parkinson-like symptoms, pyramid signs, euphoria, opticus neuritis, peripheral neuropathy, leuko-encephalopathy including ataxia, acute cerebellar syndrome, dysarthria, confusion, disorientation, myasthenia, aphasia, convulsion or coma
Excessive lacrimation, dacryostenosis, visual changes, photophobia, diplopia, decreased visus, blepharitis, ectropion
Chest pain, tachycardia, ECG-changes, angina pectoris
Arrhythmia, myocardial infarction, myocarditis, heart failure, dilatative cardiomyopathy, cardiac shock,
Cardiac arrest, sudden cardiac death
Vasculitis, Raynaud's phenomenon, cerebral ischaemia, intestinal ischaemia, peripheral ischaemia, thromboembolism
Respiratory, thoracic and mediastinal disorders
Epistaxis, dyspnea, bronchospasmus
Diarrhoea, nausea, vomiting, mucositis, stomatitis
Gastrointestinal ulceration, gastrointestinal hemorrhage
Liver cell damage
Skin and subcutaneous tissue disorders
Alopecia, palmar-plantar erythrodysesthesia
Dermatitis, hyperpigmentation, hypopigmentation, nail discoloration, nail hyperpigmentation, nail dystrophy, nailbed pain, nailbed inflammation, onycholysis, exanthema, dry skin, urticaria, photosensitivity, recall phenomenon
General disorders and administration site conditions
Thrombophlebitis, vein tracking, dehydration
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play Apple App Sore.
Manifestations of overdosage of fluorouracil can be nausea, vomiting, diarrhoea, gastrointestinal ulceration and bleeding, bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis). Patients who have been exposed to an overdose of fluorouracil should be monitored haematologically for at least four weeks. Should abnormalities appear, appropriate therapy should be utilised.
Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.
After intravenous administration, fluorouracil is distributed through the body water and disappears from the blood within 3 hours. It is preferentially taken up by actively dividing tissues and tumours after conversion to its nucleotide. Fluorouracil readily enters the C.S.F. and brain tissue.
5-fluorouracil is catabolised by the enzyme DPD to the much less toxic dihydro-5-fluorouracil (FUH2). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA). Finally, β-ureido-propionase cleaves FUPA to α-fluoro-β-alanine (FBAL) which is cleared in the urine. DPD activity is the rate limiting step. Deficiency of DPD may lead to increased toxicity of 5-fluorouracil (see section 4.3 and 4.4).
Following IV administration, the plasma elimination half-life averages about 16 minutes and is dose dependant. Following a single IV dose of fluorouracil approximately 15 % of the dose is excreted unchanged in the urine within 6 hours; over 90 % of this is excreted in the first hour. The remainder is mostly metabolised in the liver by the usual body mechanisms for uracil.
Sodium hydroxide, water for injections
Fluorouracil is incompatible with calcium folinate, carboplatin, cisplatin, cytarabine, diazepam, doxorubicin, droperidol, filgrastim, gallium nitrate, methotrexate, metoclopramide, morphine, ondansetron, parenteral nutrition, vinorelbin, other anthracylines.
Formulated solutions are alkaline and it is recommended that admixture with acidic drug preparations should be avoided.
Fluorouracil Injection, 50 mg/ml, solution for injection, is intended for single use only.
The chemical and physical in-use stability of the solution diluted with glucose or sodium chloride injection has been demonstrated for 24 hours at a temperature not exceeding 25 °C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 – 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Do not store Fluorouracil Injection, 50 mg/ml, solution for injection above 25 °C.
Do not refrigerate or freeze.
Keep the container in the outer carton.
If a precipitate has formed as a result of exposure to low temperatures, redissolve by heating to 40 °C accompanied by vigorous shaking. Allow to cool to body temperature prior to use.
Type I conventional clear glass vials, rubber closures. The rubber stopper is protected by a flanged aluminium cap with a flip-off top.
500 mg/ 10 ml:
1000 mg/ 20 ml:
2500 mg/ 50 ml:
5000 mg/100 ml:
Pack Size: Singles, 10
Pack Size: Singles, 10
Pack Size: Singles, 10
Pack Size: Singles, 10
Fluorouracil Injection, 50 mg/ml, solution for injection should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents.
Fluorouracil Injection should only be prepared for administration by professionals who have been trained in the safe use of the preparation. Preparation should only be carried out in an aseptic cabinet or suite dedicated for the assembly of cytotoxics.
In the event of spillage, operators should put on gloves, face mask, eye-protection and disposable apron and mop up the spilled material with an absorbent material kept in the area for that purpose. The area should then be cleaned and all contaminated material transferred to a cytotoxic spillage bag or bin and sealed for incineration.
Fluorouracil is an irritant, contact with skin and mucous membranes should be avoided. In the event of contact with the skin or eyes, the affected area should be washed with copious amounts of water or normal saline. A bland cream may be used to treat the transient stinging of the skin. Medical advice should be sought if the eyes are affected or if the preparation is inhaled or ingested.
a) Chemotherapeutic agents should be prepared for administration only by professionals who have been trained in the safe use of the preparation.
b) Operations such as reconstitution of powder and transfer to syringes should be carried out only under aseptic conditions in a suite or cabinet dedicated for the assembly of cytotoxics.
c) The personnel carrying out these procedures should be adequately protected with clothing, gloves and eye shield.
d) Pregnant personnel are advised not to handle chemotherapeutic agents.
All materials that have been utilised for dilution and administration should be disposed of according to standard procedures (incineration).
Fluorouracil may be diluted with 5 % glucose or 0.9 % sodium chloride intravenous infusions immediately before parenteral use. The remainder of solutions should be discarded after use; do not make up into multi-dose preparations.
Gesellschaft für klinische Spezialpräparate mbH
6 July 2000 / 11 October 2006
Theaterstrasse 6, 22880 Wedel, Germany
+44 (0)1786 458032
+44 (0)1786 458086